Conjupro Biotherapeutics Inc. Sustainability Profile
Conjupro Biotherapeutics Inc., a leading name in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2015, the company has rapidly established itself as a pioneer in developing innovative biotherapeutic solutions aimed at addressing unmet medical needs. Specialising in advanced drug delivery systems and biologics, Conjupro's core offerings include proprietary formulations that enhance therapeutic efficacy and patient compliance. Their unique approach to biotherapeutics has garnered attention, positioning them as a formidable player in the market. With a commitment to research and development, Conjupro Biotherapeutics has achieved notable milestones, including successful clinical trials and strategic partnerships that bolster its market presence. As the company continues to expand its portfolio, it remains dedicated to improving patient outcomes through cutting-edge biotherapeutic innovations.
DitchCarbon Score
How does Conjupro Biotherapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Conjupro Biotherapeutics Inc.'s score of 19 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Conjupro Biotherapeutics Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of CSPC Pharmaceutical Group Limited, which may influence its climate commitments and reporting practices. While Conjupro Biotherapeutics Inc. has not established specific reduction targets or initiatives, it is important to note that its parent company, CSPC Pharmaceutical Group Limited, may have relevant climate strategies and performance metrics that could impact Conjupro's environmental footprint. However, details regarding these initiatives are not provided in the available data. As a subsidiary, Conjupro's climate commitments may align with broader industry standards and practices, but specific commitments or targets have not been disclosed. The absence of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 1,108,844,970 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 53,566,610 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 44,547,340 | - | - | - | - | - | - |
How Carbon Intensive is Conjupro Biotherapeutics Inc.'s Industry?
How Carbon Intensive is Conjupro Biotherapeutics Inc.'s Location?
Conjupro Biotherapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Conjupro Biotherapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
